Drug Education Guide

Cemiplimab (Patient)

Immunotherapy Monoclonal antibody PD-1 inhibitor

Cemiplimab (Patient)

Immunotherapy Monoclonal antibody PD-1 inhibitor
Light Sensitive Fall Risk
Medication Basics

Drug Name

Cemiplimab (Brand names: Libtayo®)

Purpose / Indication

Used to treat certain cancers such as cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer, and other approved indications.

Dosage & Administration

Dose Schedule

Commonly administered as an intravenous infusion every 3 weeks, though dosing and duration must follow the oncology provider’s treatment plan and current protocol.

Route

IV (Intravenous)

Timing Considerations

Treatment is given in cycles. The infusion schedule is determined by the oncology team and may change if side effects occur.

Time of Day

Flexible

Special Instructions

Keep all appointments and tell your care team about new symptoms before each treatment.

Injection Techniques

This medicine is given by trained healthcare professionals through an IV line.

Mechanism of Action

Mechanism

This medicine helps your immune system recognize and attack cancer cells by blocking a signal that can turn immune cells off.

13 More Sections — Members Only

Free membership unlocks the complete guide.

  • Side Effects
  • Drug Interactions
  • Contraindications
  • Monitoring
  • Adherence
  • + 8 more…
Was this guide helpful?